ERBB3 and cancer: Furthermore, we treated cancer cells with a panel of anti-HER3 monoclonal antibodies (HER3-Mab) and inhibition of HER3 by the neutralizing antibodies (referred as A14, U59, and B11) resulted in significant decreasing of LINC00052 expression when compared to an IgG isotype control (Figure 1G).